UBS lowered the firm’s price target on Surgery Partners (SGRY) to $29 from $34 and keeps a Buy rating on the shares.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on SGRY:
- Surgery Partners Appoints New COO and President
- Strategic Growth and Portfolio Optimization Drive Buy Rating for Surgery Partners
- Surgery Partners price target lowered to $31 from $35 at RBC Capital
- Surgery Partners price target lowered to $30 from $35 at Benchmark
- Surgery Partners Reports Q3 2025 Financial Results